Abstract

Periodontal disease is a common, progressive inflammatory condition with complex causes and significant implications for both oral and overall health. This paper begins by reviewing the physiology of healthy periodontal tissues, followed by an explanation of the pathogenesis and progression of periodontal disease. In addition to its localized effects, periodontitis is increasingly recognized for its strong epidemiological associations with a range of systemic illnesses, including cardiometabolic disorders, neurodegenerative diseases, autoimmune conditions, respiratory infections, and cancer. North America currently dominates the periodontal therapeutics market, while the Asia Pacific region is rapidly establishing itself as the fastest-growing market. The global market for periodontal therapeutics continues to expand, driven by rising disease prevalence, greater awareness of oral health, an aging population, and technological advancements. Existing products such as ARESTIN, ATRIDOX, Emdogain, and BioMend membranes enhance treatment outcomes through targeted drug delivery, guided tissue regeneration, and improved surgical healing. This paper also discusses promising innovations currently in clinical trials, including advanced dentifrices, novel antibiotics, and stem cell therapies, which highlight the potential for transformative shifts in periodontal care. Together, these findings and innovations reflect a dynamic and rapidly evolving market focused on not only halting disease progression but also restoring periodontal health through scalable, personalized, and regenerative therapies.

Keywords

periodontal disease, gum disease, periodontitis, gingivitis, oral health, systemic disease associations